Related Experiment Video
Updated: Aug 1, 2025
08:02
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
Published on: March 6, 2012
16.5K
The First Survival Score for Patients Treated with Whole-Brain Radiotherapy Plus Simultaneous Integrated Boost for
Dirk Rades1, Leonie Johannwerner1, Elisa M Werner1
1Department of Radiation Oncology, University of Lubeck, 23562 Lubeck, Germany.
Biology
|April 28, 2023
Summary
Researchers developed survival scores for brain metastases patients treated with whole-brain radiotherapy plus simultaneous boost (WBRT+SIB). Models accurately predicted short-term survival, suggesting some patients may not benefit from SIB, while others could benefit from advanced models.
Area of Science:
- Neuro-oncology
- Radiation Oncology
- Medical Statistics
Background:
- Brain metastases are a common complication of cancer.
- Whole-brain radiotherapy plus simultaneous boost (WBRT+SIB) is a modern treatment approach.
- Accurate prognostic tools are needed to guide treatment decisions.
Purpose of the Study:
- To develop and validate prognostic models for survival in patients with brain metastases treated with WBRT+SIB.
- To identify key prognostic factors influencing survival.
- To compare the predictive accuracy of different models.
Main Methods:
- Development of three prognostic models using data from 128 patients treated with WBRT+SIB.
- Inclusion of prognostic factors such as Karnofsky Performance Score (KPS), number of brain metastases, age, and extra-cerebral metastases.
- Calculation of positive predictive values (PPVs) for death within 6 months and survival beyond 6 months.
Main Results:
- Multivariate analysis identified KPS and number of brain metastases as significant predictors of survival.
- All models demonstrated high accuracy in predicting death within 6 months (PPVs 83-86%).
- Models 2 (KPS, lesions, age) and 3 (KPS, lesions, age, extra-cerebral metastases) showed superior performance in predicting survival beyond 6 months (PPVs 75-78%).
Conclusions:
- Prognostic models can accurately predict short-term survival in brain metastases patients treated with WBRT+SIB.
- Patients with poor prognosis may not benefit from SIB, warranting careful consideration of treatment intensity.
- Model 2 offers a favorable balance of accuracy and data requirements for predicting longer-term survival, while Model 3 is suitable when extensive staging data is available.
